Neviah Genomics · raw details

Early Detection of Drug-induced Toxicity · Yavne · Founded 2012

inactive Series A ← back to profile

About

Early Detection of Drug-induced Toxicity

Neviah Genomics is the inventor and developer of PropheTox, a drug toxicity screening service. Based on the mathematical analysis of cell behavior following exposure to multiple toxic and non-toxic compounds, PropheTox's innovatve assay design and optimized decision support algorithms allow the detection of low-dose, chronic toxic effects. The predictive quality of the PropheTox technology is developed through an iterative process involving toxicity assays, machine learning, and prior biological knowledge. The predictor is based on non-trivial analysis of expression data from experiments exposing primary liver cells to compounds with known toxicity, and representing a wide variety of liver toxicity pathways.

Identity

NameNeviah Genomics
Slugneviah-genomics
Type / kindstartup
Crunchbase IDNeviah Genomics
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP2q3p8LDA

Status

Statusinactive
Status reasonNon Active, Oct 2017
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityYavne
HQ addressHaKishon St 18, Yavne, Israel

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcarePatientsLaboratoriesLife SciencesPharmaceuticals
Business models
B2B
Tags
biotechnologydiagnosticslaboratoriesbioinformaticspharma-companiesbiomarkersmachine-learningdrug-discovery

Funding

Total raised
Current stageSeries A

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}